Search Within

James Joseph Harding

Formats
  1. Meeting Abstract (124)
  2. Journal Article (115)
  3. Review (7)
  4. Book Section (3)
  5. Miscellaneous (3)
Groups
  1. Department of Medicine (252)
  2. Gastrointestinal Oncology Service (252)
  3. Solid Tumor Oncology Division (252)
  4. Center for Pancreatic Cancer Research (129)
  5. GSK Faculty (99)
  6. Epidemiology and Biostatistics (89)

More Groups

People
  1. Ghassan Abou-Alfa (130)
  2. Eileen O'Reilly (70)
  3. William Jarnagin (59)
  4. Michael D'Angelica (40)
  5. Andrea Cercek Hanjis (38)
  6. Michael Berger (37)

More People

Years
  1. 2025 (13)
  2. 2024 (32)
  3. 2023 (34)
  4. 2022 (21)
  5. 2021 (23)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Annals of Oncology (17)
  3. Clinical Cancer Research (15)
  4. Annals of Surgical Oncology (13)
  5. Cancer (9)
  6. JCO Precision Oncology (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (99)
  2. Oxford University Press (25)
  3. American Association for Cancer Research (23)
  4. Springer (20)
  5. Wiley Blackwell (14)
  6. Elsevier Science, Inc. (10)

More Publishers

Results (252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations
    Journal Article

    Adib, E.; Klonowska, K.; Giannikou, K.; Do, K. T.; Pruitt-Thompson, S.; Bhushan, K.; Milstein, M. I.; Hedglin, J.; Kargus, K. E.; Sholl, L. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
    Journal Article

    Brannon, A. R.; Jayakumaran, G.; Diosdado, M.; Patel, J.; Razumova, A.; Hu, Y.; Meng, F.; Haque, M.; Sadowska, J.; Murphy, B. J.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
    Journal Article

    Harding, J. J.; Do, R. K.; Yaqubie, A.; Cleverly, A.; Zhao, Y.; Gueorguieva, I.; Lahn, M.; Benhadji, K. A.; Kelley, R. K.; Abou-Alfa, G. K.
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)
    Meeting Abstract

    Sangro, B.; Harding, J. J.; Johnson, M.; Palmer, D. H.; Edeline, J.; Abou-Alfa, G. K.; Cheng, A. L.; Decaens, T.; El-Khoueiry, A. B.; Finn, R. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors
    Meeting Abstract

    Pauff, J. M.; Papadopoulos, K. P.; Janku, F.; Turk, A. A.; Goyal, L.; Shroff, R. T.; Shimizu, T.; Ikeda, M.; Azad, N. S.; Cleary, J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
    Meeting Abstract

    Pant, S.; Ducreux, M.; Harding, J. J.; Javle, M. M.; Oh, D. Y.; Wasan, H. S.; Fortenberry, A.; Josephson, N. C.; Mwatha, A.; Wang, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial
    Meeting Abstract

    Harding, J. J.; Cleary, J. M.; Quinn, D. I.; Braña, I.; Moreno, V.; Borad, M. J.; Loi, S.; Spanggaard, I.; Park, H.; Ford, J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)
    Meeting Abstract

    Abou-Alfa, G. K.; Meyer, T.; Zhang, J.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Xu, F.; Eli, L. D.; Harding, J. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 3, double-blind, randomized study of nivolumab and ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Harding, J.; Johnson, M.; Palmer, D.; Edeline, J.; Abou-Alfa, G.; Cheng, A.; Decaens, T.; El-Khoueiry, A.; Finn, R.; more...
    Journal of Vascular and Interventional Radiology (2021)

    Fulltext@MSK | Save